A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Luseco
Synonyms :
Luseogliflozin, TS 071, TS- 71, TS- 071
Class :
SGLT2 inhibitor
Brand Name :
Luseco
Synonyms :
Luseogliflozin, TS 071, TS- 71, TS- 071
Class :
SGLT2 inhibitor
Dosage Forms & Strengths
Tablets (film-coated)
2.5mg
5mg
2.5
mg
Orally
every 24 hours
Note: the dose can be increased to 5mg depending on the response of the patient
Safety and efficacy studies are not established
Refer to adult dosing
2.5
mg
Orally
every 24 hours
Note: this should be used with caution in elderly population as the physiological function in these population may be altered
the hypoglycemic activity of acarbose may be increased
the therapeutic effects of acebutolol may be enhanced
the therapeutic efficacy of luseogliflozin may be elevated
the hypoglycemic efficiency of albiglutide can be increased
the hypoglycemic effect of alogliptin may be enhanced
an increase in hypoglycemic effects of luseogliflozin may be seen
the risk of hyperglycemia may be enhanced
the hypoglycemic effects of luseogliflozin may be reduced
the hypoglycemic activity of luseogliflozin may be increased
the therapeutic activity of luseogliflozin may be reduced
the therapeutic efficiency of luseogliflozin may be elevated
the risk of hyperglycemia may be enhanced
the hypoglycemic effect of canagliflozin may be increased
the risk of renal failure hyperkalemia and hypotension may be raised
the hypoglycemic activity of chlorpropamide may be increased
the risk of hyperglycemia may be enhanced
Actions and spectrum:
Luseogliflozin is an antidiabetic drug. It works by stopping a protein called SGLT2 from absorbing too much glucose back into the body from the kidneys at the proximal tubules. By blocking SGLT2, luseogliflozin allows excess glucose to be excreted from the body through urine. In laboratory studies, luseogliflozin selectively inhibited glucose uptake by human SGLT2 cells.
Frequency not defined
Genital candidiasis
Polycythaemia
Dehydration
Dizziness
Polyuria
Pruritis genital
Thirst
Cystitis
Pyelonephritis
Hypotension
Ketoacidosis
Black Box Warning
No specific black box warning is documented
Contraindication/Caution:
Contraindication:
Hypersensitivity
Special precautions:
Renal impairment
Hepatic impairment
Polyuria
Pollakiuria
Genital infections
Infections of the urinary tract
Ketoacidosis
Pregnancy/Lactation
Pregnancy consideration:
Safety and efficiency about the use of luseogliflozin in pregnant people is not established
Lactation:
It should not be used in lactating mothers as the medication is known to be secreted into breast milk.
Formula feed should be given to the infants if luseogliflozin should be administered to mother
Pregnancy categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the foetus `in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Luseogliflozin is a novel chemical entity possessing strong inhibitory activity against sodium-dependent glucose cotransporter2.
Pharmacodynamics:
This is a selective inhibitor of SGLT2. It promotes urinary glucose excretion that leads to lowered levels of glucose in plasma. In people with type 2 diabetes mellitus, luseogliflozin provides a noticeable glycemic control.
Pharmacokinetics:
Absorption
Luseogliflozin is absorbed rapidly on oral absorption.
Distribution
96% of the drug is known to be bound to plasma proteins.
Metabolism
The drug undergoes hepatic metabolism via CYP3A4/5. The main metabolites exist is carboxyl and O-deethyl form.
Elimination and excretion
It is known to undergo elimination through urine.
Administration:
Luseogliflozin should be administered orally onetime a day before or after meals.
Patient information leaflet
Generic Name: luseogliflozin
Pronounced: loo-se-oo-gli-flow-jin
Why do we use luseogliflozin?
Luseogliflozin (TS-071) is a unique medicine that works very well at stopping the SGLT2 protein from letting sugar into the body. This medicine helps lower blood sugar levels. It was approved for use in Japan. Patients can take it alone or with other diabetes drugs.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
